John M. Burke, MD

John M. Burke, MD discussed ongoing investigations into the treatment of lymphoma that were presented at ASCO 2024.

John Burke, MD, discusses the evolution of the diffuse large B-cell lymphoma treatment paradigm.

John M. Burke, MD, discusses several ongoing or upcoming investigations of targeted therapy in mantle cell lymphoma.

John M. Burke, MD, discusses the influence of two key BTK inhibitor combination studies on therapeutic approaches for patients with previously untreated mantle cell lymphoma.

John M. Burke, MD, discusses the underrepresentation of elderly patients in clinical trials for lymphoma.

John M. Burke, MD, discusses findings from the phase 3 POLARIX trial in patients with newly diagnosed diffuse large B-cell lymphoma.

John M. Burke, MD, discusses risk stratifications strategies in follicular lymphoma. 

John M. Burke, MD, discusses treatment options in relapsed/refractory follicular lymphoma.

John M. Burke, MD, discusses the potential benefits of time-limited therapy with BTK inhibitors in B-cell malignancies.

John M. Burke, MD, discusses treatment options for patients with early-stage or advanced follicular lymphoma with a low tumor burden.

John M. Burke, MD, discusses the role of tazemetostat in EZH2-mutated follicular lymphoma.

John M. Burke, MD, discusses current indications for BTK inhibitors in B-cell malignancies.

John M. Burke, MD, discusses research with tafasitamab (MOR208) in lymphoma.

John M. Burke, MD, associate chair of the Hematology Research Program for US Oncology and medical oncologist and hematologist at Rocky Mountain Cancer Centers, discusses the ongoing phase Ib First-MIND trial in diffuse large B-cell lymphoma (DLBCL).

John M. Burke, MD, Rocky Mountain Cancer Centers, discusses the significant findings of the phase III GOYA study investigating obinutuzumab (Gazyva) plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

John M. Burke, MD, discusses the GOYA study, a phase III study investigating obinutuzumab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma. Burke discussed the study during the American Society of Hematology (ASH) Annual Meeting.